1. Home
  2. RDI vs CPHI Comparison

RDI vs CPHI Comparison

Compare RDI & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

N/A

Current Price

$1.21

Market Cap

24.8M

ML Signal

N/A

Logo China Pharma Holdings Inc.

CPHI

China Pharma Holdings Inc.

HOLD

Current Price

$0.67

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
CPHI
Founded
1937
N/A
Country
United States
China
Employees
2025
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.8M
26.3M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
RDI
CPHI
Price
$1.21
$0.67
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
22.6K
8.7K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,144,268.00
Revenue This Year
$16.25
N/A
Revenue Next Year
$4.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.50
52 Week High
$1.65
$2.60

Technical Indicators

Market Signals
Indicator
RDI
CPHI
Relative Strength Index (RSI) 62.42 53.77
Support Level $0.99 $0.53
Resistance Level $1.31 $1.88
Average True Range (ATR) 0.06 0.05
MACD 0.01 0.01
Stochastic Oscillator 86.36 72.33

Price Performance

Historical Comparison
RDI
CPHI

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.

Share on Social Networks: